News | News By Subject | News by Disease News By Date | Search News

Lymphoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
FDA Calls It! Seattle Genetics (SGEN)' Adcetris is a Breakthrough for Lymphoma     11/14/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma     8/1/2016
Celgene (CELG)'s Revlimid Fails to Extend Survival in Lymphoma Study     7/26/2016
Genentech (RHHBY) Receives a Blow After Lymphoma Drug Flunks Phase III Test     7/19/2016
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study     5/27/2016
FDA Lifts Partial Clinical Hold on Medivation (MDVN)'s Pidilizumab     3/9/2016
FDA Green Lights Genentech (RHHBY)'s Gazyva for Patients with Previously Treated Follicular Lymphoma     2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal     2/26/2016
Analyst Questions High Cost of T Cell Therapies as Potential Frontline Treatment for Blood Cancers     2/25/2016
Medivation (MDVN) Stock Falls After the FDA Places Partial Clinical Hold on MDV9300     1/27/2016
Novartis AG (NVS) Takes Another 2.5% Stake in Gamida Cell     10/12/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec     7/2/2015
ASCO15 EXCLUSIVE: Genentech (RHHBY) VP Tells BioSpace (DHX) Gazyva a "Clear Advance" For NHL Treatment     6/1/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial     3/20/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015

News from Around the Web
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Kite Pharma (KITE)'s CEO On Cancer-Killing T-Cells: "This Is A Revolution"     2/29/2016
BioSpace’s Favorite FDA Tricks Or Treats     10/24/2014
Novel Drug Shuts Down Master Protein Key to Lymphoma, Weill Cornell Medical College Study     8/5/2013
New Technique Catalogs Lymphoma-Linked Genetic Variations, Johns Hopkins University School of Medicine Study     12/27/2012
B-Cell Lymphoma: New Research Provides Breakthrough in Understanding Common Cancer, University of Sheffield Study     6/10/2011
"Sniffing Out" Lymphoma Genes by Turning Dogs into Humans, North Carolina State University Study     4/7/2011
Gene Mutation Linked to Deadly Lymphoma, University of Rochester Study     1/3/2011
National Institutes of Health (NIH) Scientists Identify Possible Gene Target for Treating a Form of Lymphoma     12/29/2010
Conjugate Drug Shows Benefit in Lymphoma, University of Texas Study     11/4/2010
Hepatitis B Linked To Lymphoma In National Cancer Institute and Sun Ha Jee of Yonsei University Study     8/4/2010
Vitamin K May Protect Against Developing Non-Hodgkin's Lymphoma, Say Mayo Clinic Researchers     4/21/2010
Seaweed Extract May Hold Promise for Non-Hodgkin's Lymphoma Treatment, The Hashemite University Study     3/11/2010
Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer, University of Rochester Medical Center Study     11/6/2009
Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB)'s Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma, Rabin Medical Center (Beilinson Hospital) Study     2/11/2009

Press Releases
AbbVie (ABBV) Release: New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA)     12/6/2016
Arvinas Collaborators Present Data On BET PROTAC Degraders At 2016 American Society of Hematology Annual Meeting     12/6/2016
Juno (JUNO) Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma     12/6/2016
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS®(Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting     12/6/2016
Nordic Nanovector: Betalutin In Combination With Rituximab Demonstrates Synergistic Anti-Tumour Effect In Preclinical Non-Hodgkin Lymphoma Model     12/6/2016
Novartis AG (NVS) Presents Results From First Global Registration Trial Of CTL019 In Pediatric And Young Adult Patients With R/R B-ALL     12/5/2016
Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)     12/5/2016
Genentech (RHHBY)’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan     12/5/2016
Seattle Genetics (SGEN) Highlights Long-Term Follow-Up Data From ADCETRIS® (Brentuximab Vedotin) In T-Cell Lymphomas At American Society of Hematology Annual Meeting     12/5/2016
Merck & Co. (MRK) Release: Updated KEYTRUDA (Pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society of Hematology     12/5/2016
Celltrion Healthcare (068270.KQ) Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma     12/5/2016
Kite Pharma (KITE) Initiates Rolling Submission Of U.S. Biologics License Application (BLA) For KTE-C19, Its Investigational Anti-CD19 CAR-T Therapy, For The Treatment Of Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)     12/5/2016
FDA Grants Priority Review To Supplemental Biologics License Application (sBLA) For Merck & Co. (MRK)'s KEYTRUDA (Pembrolizumab) In Relapsed Or Refractory Classical Hodgkin Lymphoma     12/1/2016
European Commission (EC) Approves Bristol-Myers Squibb (BMY)'s Opdivo(Nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin     11/23/2016
Kite Pharma (KITE) To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society of Hematology Annual Meeting     11/21/2016

//-->